Perinatal Depression: Prevalence, Screening Accuracy, and Screening Outcomes

Gaynes BN, Gavin N, Meltzer-Brody S, Lohr KN, Swinson T, Gartlehner G, Brody S, Miller WC. Perinatal Depression: Prevalence, Screening Accuracy, and Screening Outcomes. Evidence Report/Technology Assessment No. 119. (Prepared by the RTI-University of North Carolina Evidence-based Practice Center, under Contract No. 290-02-0016.) AHRQ Publication No. 05-E006-2. Rockville, MD: Agency for Healthcare Research and Quality. February 2005.

 

Links

• Full report
• Obstetrics & Gynecology article

 

Related Documents

• None

 

Abstract

Context

Depression during pregnancy or the first year postpartum is impressively common and can have devastating consequences for the woman, her children, and other family members.

Objectives

We systematically review the evidence on (1) the prevalence and incidence of perinatal depression, (2) the accuracy of different screening instruments, and (3) the effectiveness of interventions for women screened as high risk for perinatal depression.

Data Sources

MEDLINE, CINAHL, PsycINFO, Sociofile, and the Cochrane Library (1980 through March 2004); bibliographic hand searches; and experts.

Study Selection

The English-language studies assessed women for major depression alone or for major or minor depression. Studies of the prevalence and incidence of depression and the accuracy of screening tools had to include diagnostic confirmation by a reference standard. Studies involving interventions required a comparison group. Two reviewers independently evaluated each abstract to determine inclusion by consensus.

Data Extraction

A primary reviewer abstracted data on key variables from the articles directly into detailed evidence tables; a second reviewer confirmed accuracy.

Data Synthesis

We conducted a meta-analysis of the prevalence and incidence estimates to compute combined estimates for particular periods and points in time. We also conducted meta-analyses of the sensitivity and specificity of different screening instruments. For screening outcome studies, we were only able to synthesize qualitatively.

Results

We identified 30 studies of prevalence. For major depression alone, point prevalence estimates ranged from 3.1 percent to 4.9 percent at different times during pregnancy and 1.0 percent to 5.9 percent at different times during the first postpartum year. For major and minor depression, estimates of the point prevalence ranged from 8.5 percent to 11.0 percent during pregnancy and 6.5 percent to 12.9 percent during the first year postpartum. However, these prevalence estimates were not significantly different from those of similarly aged nonchildbearing women. Data on incidence were more limited.

We identified 10 studies of screening accuracy. One small study reported on accuracy during pregnancy. For postpartum depression, screeners appeared feasible, but the small number of depressed patients involved precluded identifying an optimal screener or threshold for screening. Screening instruments studied are generally good at identifying major depression alone, with accuracy consistent with reports from primary care settings, but they performed poorer for the major or minor depression category.

We found no studies directly testing whether screening improved outcomes. However, we identified 15 studies that used some sort of screening to identify women at risk of depression and
for whom a subsequent intervention was provided. The results of four small studies of various psychosocial interventions during pregnancy did not demonstrate consistently superior outcomes. Results were also mixed for postpartum interventions. Six of nine studies of various psychosocial interventions reported significant improvement in depression for the experimental group. Two studies with pharmacologic interventions provided conflicting results.

Conclusions

Our findings indicate that the existing evidence does not warrant the choice of one second-generation antidepressant over another based on greater efficacy and effectiveness. Differences with respect to onset of action and adverse events may be taken into consideration for the choice of a medication.